0001493152-18-010074.txt : 20180716
0001493152-18-010074.hdr.sgml : 20180716
20180716200015
ACCESSION NUMBER: 0001493152-18-010074
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20180712
FILED AS OF DATE: 20180716
DATE AS OF CHANGE: 20180716
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Moscato Robert Jr.
CENTRAL INDEX KEY: 0001723420
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 000-13789
FILM NUMBER: 18955347
MAIL ADDRESS:
STREET 1: 400 PRATT STREET
STREET 2: SUITE 606
CITY: BALTIMORE
STATE: MD
ZIP: 21202
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: Marina Biotech, Inc.
CENTRAL INDEX KEY: 0000737207
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
IRS NUMBER: 112658569
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 17870 CASTLETON STREET
STREET 2: SUITE 250
CITY: CITY OF INDUSTRY
STATE: CA
ZIP: 91748
BUSINESS PHONE: 4259083600
MAIL ADDRESS:
STREET 1: 17870 CASTLETON STREET
STREET 2: SUITE 250
CITY: CITY OF INDUSTRY
STATE: CA
ZIP: 91748
FORMER COMPANY:
FORMER CONFORMED NAME: MDRNA, Inc.
DATE OF NAME CHANGE: 20080610
FORMER COMPANY:
FORMER CONFORMED NAME: NASTECH PHARMACEUTICAL CO INC
DATE OF NAME CHANGE: 19920703
4
1
ownership.xml
X0306
4
2018-07-12
0
0000737207
Marina Biotech, Inc.
MRNA
0001723420
Moscato Robert Jr.
C/O MARINA BIOTECH, INC.
17870 CASTLETON STREET, SUITE 250
CITY OF INDUSTRY
CA
91748
1
1
0
0
Chief Executive Officer
Series F Convertible Preferred Stock
0.50
2018-07-12
4
P
0
40
5000
A
2018-07-12
common stock
400000
40
I
See footnote
Warrants to Purchase Common Stock
0.55
2018-07-12
4
P
0
300000
0.00
A
2018-07-12
common stock
300000
300000
I
See footnote
Each outstanding share of Series F Preferred Stock shall be converted into common stock on the earliest to occur of: (i) any date more than 30 trading days after the closing of the issuer's private placement of shares of its Series F Preferred Stock and warrants to purchase shares of its common stock (the "Offering") that the closing price of the Issuer's common stock on each of the trading days immediately prior to such conversion exceeds $5.00; (ii) the three year anniversary of the closing of the Offering; and (iii) the date on which the holders of a majority of the outstanding shares of Series F Preferred Stock elect to convert all of the outstanding shares of Series F Preferred Stock.
The reporting person is the majority member and manager of the general partner of the entity that holds the applicable securities. In such position, the reporting person has the power to control the voting and disposition of the applicable securities.
The warrants expire on the five year anniversary of the closing of the Offering.
/s/ Robert C. Moscato, Jr.
2018-07-16